Modality
Fusion Protein
MOA
PCSK9i
Target
FGFR
Pathway
PI3K/AKT
Atopic Derm
Development Pipeline
Preclinical
~Aug 2012
→ ~Nov 2013
Phase 1
~Feb 2014
→ ~May 2015
Phase 2
~Aug 2015
→ ~Nov 2016
Phase 3
Feb 2017
→ Oct 2026
Phase 3Current
NCT06999812
839 pts·Atopic Derm
2024-11→2025-04·Terminated
NCT06843845
229 pts·Atopic Derm
2020-04→TBD·Active
NCT08807244
1,381 pts·Atopic Derm
2017-02→2025-11·Recruiting
+1 more trial
3,471 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-04-0212mo agoPh3 Readout· Atopic Derm
2025-11-264mo agoPh3 Readout· Atopic Derm
2026-10-106mo awayPh3 Readout· Atopic Derm
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P3
Recruit…
P3
Complet…
P3
Active
P3
Termina…
Catalysts
Ph3 Readout
2025-04-02 · 12mo ago
Atopic Derm
Ph3 Readout
2025-11-26 · 4mo ago
Atopic Derm
Ph3 Readout
2026-10-10 · 6mo away
Atopic Derm
RecruitingActiveCompletedTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06999812 | Phase 3 | Atopic Derm | Terminated | 839 | UPCR |
| NCT06843845 | Phase 3 | Atopic Derm | Active | 229 | ACR20 |
| NCT08807244 | Phase 3 | Atopic Derm | Recruiting | 1381 | VA |
| NCT03425609 | Phase 3 | Atopic Derm | Completed | 1022 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| INC-1261 | Incyte | Phase 1/2 | PRMT5 | |
| Mavutuximab | Hansoh Pharma | Phase 2/3 | PI3Kα | |
| Tixatapinarof | Recursion | Approved | FGFR |